Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 1 3Phase 1/2 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Hypertension 2Diabetes Mellitus, Type 2 2Cushing Syndrome 2ACTH Syndrome, Ectopic 2Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × relacorilant × Clear all
NCT04308590 2025-09-04

GRADIENT

Corcept Therapeutics

Phase 3 Completed
137 enrolled 25 charts

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension

NCT03697109 2025-07-16

GRACE

Corcept Therapeutics

Phase 3 Completed
152 enrolled 28 charts
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Pituitary ACTH Hypersecretion

NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Corcept Therapeutics

Phase 3 Active not recruiting
381 enrolled 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04329949 2023-11-18

RELIANT

Corcept Therapeutics

Phase 3 Terminated
43 enrolled 17 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡